Clinical trials: Ocular Surface
Tears; Excess, Eyelid Spasm
Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure
The purpose of this research study is to test if Topical (applied to the surface of the eye) Botulinum Toxin temporarily lowers the upper eyelid and makes the eyelid appear less open and thereby affects the eye surface and…
- Trial name
- NCT06080438
- Testing
- Botulinum toxin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Miami
Dry Eye Syndrome, Lipid Deficiency
Evaluation of SYSTANE® BALANCE in Dry Eye Subjects With Lipid Deficiency
The purpose of this study is to evaluate the repeated use of SYSTANE® BALANCE on stabilizing the tear film of dry eye patients with an unstable tear film.
- Trial name
- NCT01688726
- Testing
- SYSTANE® BALANCE eyedrops, Minims® Saline 0.9% eyedrops
- Volunteers
- 91 people
- Sponsor
- Alcon Research
Ophthalmological Agent Toxicity, Bacterial Conjunctivitis
Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects
This is a phase I clinical study evaluating the safety and tolerability of PRO-231 ophthalmic solution through the incidence of unexpected adverse events, incidence of conjunctival hyperemia and chemosis, changes in Best…
- Trial name
- NCT06363292
- Testing
- PRO-231, VIGAMOXI®
- Where
- Mexico
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Open-angle Glaucoma, Ocular Hypertension
Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00690794
- Testing
- Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®), Latanoprost ophthalmic solution 0.005% (XALATAN®)
- Volunteers
- 726 people
- Sponsor
- Alcon Research
Glaucoma
Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®
Therapeutic indication: Ocular hypotensive Use: Primary open-angle glaucoma and ocular hypertension. Objectives: To evaluate the safety and tolerability of the preservative-free formulation PRO-122 manufactured by Sophia…
- Trial name
- PRO-122/I (NCT03966365)
- Testing
- PRO-122, Krytantek Ofteno®
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye
Efficacy and Safety Study of FID 119515A
The purpose of this study was to compare the effect of FID 119515A to Blink® Tears on the integrity of tear film in adults with a history of dry eye in both eyes.
- Trial name
- NCT01833117
- Testing
- FID 119515A, Blink® Tears
- Volunteers
- 75 people
- Sponsor
- Alcon Research
Cataract, Myopia
Effect of TrueTear Corneal Surface Imaging
This study will evaluate the utility of TrueTear™ to improve anterior corneal surface imaging quality before cataract surgery, refractive lens exchange, or laser refractive surgery.
- Trial name
- NCT03637348
- Testing
- TrueTear
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Price Vision Group
Limbal Stem Cell Deficiency
Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.
- Trial name
- CALEC (NCT02592330)
- Testing
- Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Dry Eye, Sjogren's Syndrome
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Severe dry eye is a debilitating ocular disease resulting in loss of vision, reduced day-to-day function and significant discomfort.
- Conditions
- Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
- Trial name
- NCT01393132
- Testing
- Thymosin Beta 4 eye drops, Vehicle Control
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Michigan Cornea Consultants, PC
Keratoconjunctivitis Sicca, Dry Eye Syndrome
Effects of Dry Eye Treatments on the Ocular Surface
The purpose of this study is to evaluate whether, in people with dry eye syndrome, over the counter artificial tears and the prescription eye drop, dexamethasone, change or effect the eyes response to a low humidity environment.
- Trial name
- NCT01797822
- Testing
- Dexamethasone, Artificial tear
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Conjunctivitis, Conjunctivitis, Bacterial
Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects
Phase I clinical trial, to evaluate the safety and tolerability of the ophthalmic solution PRO-174 versus Sophixín Ofteno®, elaborated by Laboratorios Sophia, S.A. of C.V.
- Trial name
- PRO-174/I (NCT03519516)
- Testing
- PRO-174, Sophixín Ofteno®
- Where
- Mexico
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Cataract
Surveillance of Ocular Surface Flora (SURFACE)
Topical fluoroquinolones (FQs) have achieved widespread use in ophthalmology for both the treatment and prophylaxis of ocular infections.
- Trial name
- NCT00621933
- Where
- United States
- Volunteers
- 399 people
- Sponsor
- Allergan
Dry Eye
Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye
To determine efficacy and safety profile of dexamethasone 0.4mg lacrimal insert in dry eye related ocular surface inflammation.
- Trial name
- NCT04498468
- Testing
- Sustained Release Dexamethasone, 0.4 mg, E-Caprolactone-L-Lactide copolymer (PCL) punctal plug
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Hyperemia Eye
Safety and Tolerability of PRO-185
Phase I Study to evaluate safety and tolerability of PRO-185 (naphazoline/hypromellose) ophthalmic solution through evaluation of vital signs, ocular signs such as intraocular pressure, hyperemia and mydriasis and adverse events.
- Trial name
- PRO-185 (NCT05470868)
- Testing
- Naphazoline / Hypromellose Ophthalmic
- Where
- Mexico
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Dry Eye Syndrome
Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining
The purpose of this study is to compare Systane® ULTRA lubricant eye drops to OPTIVE® lubricating eye drops for ocular surface staining within dry eye subjects and to evaluate the safety of Systane® ULTRA after 3 months of use.
- Trial name
- NCT01863368
- Testing
- Preservative-free saline solution eyedrops, Systane® ULTRA lubricant eyedrops, OPTIVE® lubricating eyedrops
- Volunteers
- 105 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Acupuncture for Dry Eye Syndrome
This study is about the effectiveness of acupuncture treatment on dry eye syndrome. Study hypothesis is that a standardized acupuncture would be more effective than a sham acupuncture in dry eye syndrome patients.
- Trial name
- NCT00969280
- Testing
- Standardized Acupuncture, Non-acupuncture point shallow penetration acupuncture
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Korea Institute of Oriental Medicine
Glaucoma, Open-Angle, Ocular Hypertension
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution…
- Trial name
- NCT01253902
- Testing
- bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%
- Where
- 2 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Allergan